Jazz Pharmaceuticals (JAZZ) Non-Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• In Q1 2026, Non-Current Assets fell 1.76% year-over-year to $7.3 billion; the TTM figure through Mar 2026 stood at $30.0 billion (down 1.22% YoY), while the FY2025 annual figure was $7.5 billion, up 1.49% from the prior year.
• Non-Current Assets was $7.3 billion for Q1 2026 at Jazz Pharmaceuticals, down from $7.5 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $9.3 billion in Q1 2022 to a low of $7.3 billion in Q1 2026.
• Historically, Non-Current Assets has averaged $7.9 billion across 5 years, with a median of $7.8 billion in 2022.
• Biggest YoY gain for Non-Current Assets was 158.19% in 2022; the steepest drop was 20.68% in 2022.
• A 5-year view of Non-Current Assets shows it stood at $8.2 billion in 2022, then fell by 3.3% to $8.0 billion in 2023, then retreated by 7.22% to $7.4 billion in 2024, then increased by 1.49% to $7.5 billion in 2025, then declined by 2.89% to $7.3 billion in 2026.
• The last three Non-Current Assets figures came in at $7.3 billion (Q1 2026), $7.5 billion (Q4 2025), and $7.6 billion (Q3 2025), per Business Quant data.